AIDS: Still a Problem, Still Big Business for Pharma
On World AIDS Day, checking in on the progress of treatments.
HIV, the infection that leads to AIDS, affects 33 million people worldwide -- including over one million people in the US. More than 20 years after the discovery of the disease, Big Pharma and the US government are making every effort to combat its spread, while also creating a more comfortable way of life for those already living with HIV.
"We have made progress, but we face an unending pandemic, one that spares no one, that unfortunately, disproportionately affects the most vulnerable, and which is the defining health challenge of our times," said Secretary of State Hillary Rodham Clinton in an address on Monday.
President Obama is addressing the issue through a program created by the previous administration, the President's Emergency Plan for AIDS Relief (PEPFAR). Later this week, leaders of the program will outline their five-year plan for transitioning the program from an emergency response vehicle to a sustainable health system. The President will also implement the repeal of the "HIV entry ban," a policy that prevented people living with HIV/AIDS from entering the US.
But the government isn't leading the fight against the disease -- Big Pharma is. Each of the major drugmakers has been doing its part to advance the treatment of HIV/AIDS.
Bristol-Myers Squibb (BMY) -- which brought in $1.9 billion in the first nine months of this year on its two solely-owned HIV medicines -- announced Monday that it's teaming up with the National AIDS Fund, a philanthropic organization, to further investigate why some 640,000 Americans living with HIV are going untreated or are receiving substandard care.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter